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ABSTRACT The ubiquitous transcription factor NF-KB is
regulated by its cytoplasmic inhibitor IKB. A variety of cellular
stimuli cause the dissociation of NF-#cB from IKB, allowing
NF-KB to translocate to the nucleus and regulate gene expres-
sion. Although the activation ofNF-KB in vivo is associated with
the phosphorylation and degradation of IKBa, it has remained
unclear how each of these events contributes to this process.
Recently, studies utilizing protease inhibitors have suggested
that the proteolysis of IKBa is a necessary event in the
activation of NF-ucB. We demonstrate in this study that these
and an additional protease inhibitor also completely repress
inducible phosphorylation of IKBa. This surprising result
suggests a more complex role of proteases in NF-KB activation.
In addition, data presented here indicate that many of these
inhibitors also directly modify NF-KB and inhibit its DNA
binding activity. Due to the pleiotropic effects of these protease
inhibitors, it is difficult to conclude from their use how IKBa
phosphorylation and degradation contribute to NF-KB activa-
tion. In the present study, a more direct approach demon-
strates that phosphorylation of IKBa alone is not sufficient for
NF-KB activation.
The NF-KB/Rel transcription factor family regulates a vari-
ety of genes whose products are involved in diverse biolog-
ical processes including cell growth, inflammation, and im-
mune responses (1, 2). Members of this family, which in-
cludes the proteins NFKB1 (p105/p50), NFKB2 (p100/p52),
RelA (p65), c-Rel, and RelB, are present within cells as
functionally-distinct homo- and heterodimers (1, 2). Inducible
complexes of this family are collectively referred to as
NF-KB. Typically, inactive NF-KB is found in the cytoplasm
complexed to its inhibitor, IKB (3, 4). Treatment of cells with
a large array of inducers, including tumor necrosis factor a
(TNFa), interleukin 1,3, and lipopolysaccharide (LPS), re-
sults in the dissociation of NF-KB from IKB. This allows
liberated NF-KB to translocate to the nucleus and modulate
target gene expression (1-4). Initial in vitro studies on the
mechanism of NF-KB activation have suggested that phos-
phorylation of IKBa may be sufficient for its release from
NF-KB (5, 6). Consistent with this model, a phosphorylated
form of IKBa can be detected after treatment of cells with
various inducers of NF-KB (7, 8). However, the role of IKBa
phosphorylation in vivo has yet to be determined. It was also
observed in vivo that IKBa was rapidly degraded after its
phosphorylation (7-10). The ability of activated NF-KB to
directly stimulate IKBa gene expression (11-13) results in the
reaccumulation of inactive NF-KB-IKBa complexes in the
cytoplasm.
More recent studies have addressed whether events in
addition to phosphorylation may be required for NF-KB
activation. In particular, the role of IKB proteolysis has been
investigated (10, 11, 14-18). It has been demonstrated that
IKBa is extremely unstable unless complexed with NF-KB
family members (10, 15). Thus, it was proposed that the
degradation of IKBa observed in vivo was a consequence of
its dissociation from NF-KB and not a prerequisite for acti-
vation. However, other work has suggested that degradation
of IKBa was necessary for NF-KB activation. It was found
that pretreatment of cells with a variety of serine protease
inhibitors prevented not only the degradation of IKBa but
also the activation of NF-KB (11, 16-18). Here we demon-
strate that many of the protease inhibitors utilized in these
aforementioned studies have additional effects, including an
ability to directly modify NF-KB and block its interaction
with DNA. Significantly, all of the protease inhibitors effec-
tive in the repression of IKBa degradation also prevent its
inducible phosphorylation. This dramatic result suggests that
proteases may regulate multiple events necessary for NF-KB
activation. Since these protease inhibitors interfere with both
the phosphorylation and degradation of IKBa, it is difficult to
ascertain from their use how each of these events contributes
to NF-KB activation. As reported here, the finding that
induced phosphorylation of IKBa does not cause its rapid
dissociation from NF-KB is an important step in elucidating
the mechanism(s) of NF-KB activation.
MATERIALS AND METHODS
Cell Culture and Reagents. HeLa S3 and Jurkat T cells were
grown as described (8). THP-1 cells were grown in RPMI
1640 medium containing 10%o (vol/vol) fetal calf serum,
penicillin (100 units/ml), and streptomycin (100 pg/ml). LPS,
3,4-dichloroisocoumarin (DCIC), 7-amino-1-chloro-3-
tosylamido-2-heptanone ("N1'-p-tosyl-L-lysine chloromethyl
ketone," Sigma; TLCK), L-1-tosylamido-2-phenylethyl chlo-
romethyl ketone ("N-tosyl phenylalanine chloromethyl ke-
tone," Sigma; TPCK), and N-benzoyl-L-tyrosine ethyl ester
(BTEE) were obtained from Sigma; 4-(2-aminoethyl)benze-
nesulfonyl fluoride (AEBSF) was from Boehringer Mann-
heim; TNFa was from Promega; and okadaic acid was from
LC Laboratories (Woburn, MA). TPCK was dissolved in
ethanol; TLCK was dissolved in 20 mM sodium phosphate;
DCIC, BTEE, and okadaic acid were dissolved in dimethyl
sulfoxide; AEBSF was dissolved in H20; and LPS was
dissolved in phosphate-buffered saline (PBS). These solvents
had no detrimental effect in vivo or in vitro on NF-#cB
activation or its ability to bind DNA. Concentrations of
protease inhibitors used and time ofincubation were not toxic
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to cells and are detailed in Fig. 1 unless otherwise indicated.
Okadaic acid was used at 1 pM, LPS was at 10 ,g/ml, and
TNFa was at 10 ng/ml. Bacterially expressed ReIA was a gift
from C. Rosen (Human Genome Sciences, Rockville, MD).
Preparation of Extracts and Electrophoretic Mobility Shift
Assays (EMSAs). Nuclear and cytoplasmic extracts were
prepared as described (8). Samples standardized by protein
concentration (19) were analyzed by EMSA as detailed (20).
Probe sequences were as follows: NF-KB, 5'-CAGGGC-
TGGGGATTCCCCATCTCCACAGTTTCACTTC-3';
AP-1, 5'-TTCCGGCTGACTCATCAAGCG-3; OCT-1, 5'-
TTCACGCGGTAATGAGATGGGTT-3'; SRE, 5'-CCTT-
TACAACAGGATGTCCATATTAGGACATCTGCGT-
CAGCAG-3'. Deoxycholate (DOC) activation of NF-KB in
vitro was performed by treating cytoplasmic extracts with
0.8% DOC for 5 min followed by the addition ofNonidet P-40
(NP-40) to 1.6% (4). For in vitro experiments, nuclear and
cytoplasmic extract or 1 A4 ofbacterially expressed RelA was
incubated for 1 h at 40C in binding buffer (20) lacking
dithiothreitol (DTT) but containing the indicated concentra-
tions of protease inhibitors. For some experiments DTT was
also added. Cytoplasmic extracts were then incubated with
DOC/NP-40. Subsequently, DTT, dI/dC, and labeled probe
were added and samples were analyzed by EMSA.
Immunoprecipitatlon and Western Blot Analysis. Polyclo-
nal RelA antibody (Rockland, Boyertown, PA; 2 jul of serum)
was added to 400 /lg of cytoplasmic extract and the volume
was adjusted to 200 pI with lysis buffer (10 mM Hepes, pH
7.6/60 mM KCl/1 mM EDTA/0.3% NP-40/1 mM DTT/1
mM phenylmethylsulfonyl fluoride). The samples were incu-
bated for 2 h at 40C with mixing. The extract was then added
to 20 pd of protein A-Sepharose previously blocked with 1%
bovine serum albumin and incubated for another 2 h at 40C
with mixing. Pelleted protein A-Sepharose was washed twice
with 500 A4 of lysis buffer and once with lysis buffer lacking
NP-40 and then resuspended in 20 p4 of buffer (without
NP-40). DOC was then added to 0.8% to release IKBa. Using
DOC instead of boiling to dissociate IKBa from NF-KB
significantly reduced the background on Western blots. The
supernatant, containing IKBa previously bound to RelA, was
then analyzed on Western blots. For Western blot analysis,
samples were separated by SDS/PAGE, transferred to ni-
trocellulose, and probed with the IKBa antibody (Rockland).
RESULTS
Protease Inhibitors Prevent NF-KB Activation as Assayed by
EMSAs. Consistent with previous results (16), pretreatment
of HeLa or Jurkat T cells with the serine protease inhibitor
TPCK, TLCK, BTEE, orDCIC prevented subsequentTNFa
induction of NF-KB as quantitated by EMSAs of nuclear
extracts (Fig. 1A). We demonstrate here that another serine
protease inhibitor, AEBSF, had a similar effect. Other pro-
tease inhibitors, including chymostatin, leupeptin, and Na-
benzoyl-L-arginine ethyl ester, did not prevent NF-KB acti-
vation when tested at various concentrations (data not
shown). To demonstrate that NF-KB from cells treated with
protease inhibitors retains the capacity to bind DNA, EMSAs
of corresponding cytoplasmic extracts were performed after
treating extracts with the disrupting agent DOC. DOC acti-
vates NF-KB in vitro by causing its dissociation from IKB (4).
Surprisingly, many ofthe protease inhibitors (TPCK, TLCK,
and DCIC) suppressed the ability ofDOC-activated NF-KB to
bind DNA (Fig. 1B). As a control, it was confirmed that DOC
can dissociate IKB from NF-KB in extracts from cells treated
with any of the protease inhibitors (data not shown). BTEE
and AEBSF did not negatively affect NF-KB binding (Fig.
1B). Pretreatment of cells with lower concentrations of
protease inhibitors for shorter periods yielded similar results.
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FIG. 1. In vivo effects of protease inhibitors on NF-KB activation
and DNA binding. HeLa and Jurkat T cells were pretreated with
protease inhibitors and then stimulated with TNFa for 15 min. Final
concentration of inhibitors: TPCK, 50 paM; TLCK, 300 tM; BTEE,
2 mM (HeLa) or 1 mM (Jurkat); AEBSF, 1 mM (HeLa) or 2 mM
(Jurkat); DCIC, 45 ,uM. The preincubation time prior to TNFa
addition was 30 min for TPCK, TLCK, BTEE, and DCIC and was
180 (HeLa) or 90 (Jurkat) min for AEBSF. (A) Nuclear extracts
(NEs), isolated from cells treated as indicated above each lane, were
assayed by EMSA. Two major NF-KB complexes are induced by
TNFa in HeLa cells but only one was induced in Jurkat cells. Inh.,
inhibitor. +, Added; -, not added. (B) Cytoplasmic extracts (CEs)
corresponding to the NEs used in A were either directly assayed or
were first treated with 0.8% DOC to dissociate IKB from NF-KB and
then assayed. Two NF-KB complexes are induced by DOC. InA and
B, NF-KB is indicated by a large arrow and the nonspecific band (ns)
is indicated by a small arrow. Free probe is not shown. (C) HeLa
NEs used in A were examined by EMSA for binding of other
transcription factors. The complexes specific for each probe were
competed with a 100-fold excess identical unlabeled probe but not
with a 100-fold excess KB probe (data not shown). Only specific
complexes are shown. The identity of each probe is indicated to the
left.
higher concentrations. EMSAs of nuclear extracts from cells
treated with only TPCK, TLCK, or DCIC indicated that
these agents also suppressed basal NF-KcB DNA binding
activity, including that of NFKB1 homodimers (data not
shown).
We also examined the effect ofthese protease inhibitors on
the binding of other transcription factors. AP-1 DNA binding
activity in nuclear extracts from cells treated with TNFa and
TPCK, TLCK, or DCIC (but not BTEE and AEBSF) was
also inhibited (Fig. 1C). However, not all proteins were
affected similarly. The binding of Oct-i and a protein com-
plex that specifically binds the serum response element were
not significantly altered by the various protease inhibitors.
Therefore, the inhibitory activities of TPCK, TLCK, and
DCIC on NF-KB and AP-1 DNA binding potential appear
specific. These results imply that TPCK, TLCK, and DCIC,
in addition to their antagonism of protease activity, may
Biochemistry: Finco et al.
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directly modify NF-KB and alter its ability to interact with
DNA. However, it is also conceivable that these agents
indirectly affect NF-KB and its DNA binding potential. To
explore these possibilities, we tested the effects of these
inhibitors on NF-KB binding in vitro.
Modification of NF-cB by Certain Protease Inhibitors Re-
presses its Ability to Interact with DNA. If the protease
inhibitors directly modify NF-KB in vivo, a similar effect may
be reproduced in vitro. Alternatively, if the protease inhibi-
tors initiate a cellular response that indirectly suppresses
NF-KB DNA binding, an effect in vitro would not be expected
since most cellular processes are inactive under these assay
conditions. Nuclear extracts from TNFa-stimulated cells,
containing activated NF-KB free of IKB, were investigated
first. In vitro treatment of these extracts with increasing
concentrations ofTPCK, TLCK, or DCIC inhibited the DNA
binding of activated NF-KB (Fig. 2A). Untreated cytoplasmic
extracts containing inactive NF-KB complexed to IKB were
then analyzed. These extracts were treated with DOC after
incubation with protease inhibitors to allow analysis ofDNA
binding by NF-KB. As shown in Fig. 2B, TPCK, TLCK, and
DCIC also inhibited the DNA binding potential of cytoplas-
mic NF-KB. BTEE and AEBSF, protease inhibitors that did
not alter the binding of NF-KB when added in vivo (Fig. 1B),
also had no effect in vitro (Fig. 2A andB and data not shown).
Finally, the effects of these protease inhibitors on the bac-
terially expressed RelA subunit ofNF-KB were examined. In
these experiments, the possible contribution of other cellular
proteins in mediating the effects of TPCK, TLCK, or DCIC
on NF-KB DNA binding was eliminated since only ReLA and
exogenously added bovine serum albumin were present.
Consistent with the above results, TPCK, TLCK, and DCIC
inhibited the ability of RelA to bind DNA (Fig. 2C). The
protease inhibitors do not directly modify the KB DNA probe
used in the EMSA since prolonged incubation of the probe
with concentrations of TPCK, TLCK, or DCIC that com-
pletely suppressed NF-KB binding in vivo and in vitro had no
inhibitory effect when the probe was subsequently diluted (to
substantially lower the concentration of protease inhibitor)
and used in an EMSA (data not shown). Furthermore, as
determined by Western blot analysis, NF-KB is not degraded
in vivo or in vitro in the presence of TPCK, TLCK, or DCIC
(data not shown). Thus, these results strongly suggest that
many of the protease inhibitors previously utilized in studies
of NF-KB can directly interfere with the ability of this
transcription factor to bind DNA (also see Discussion).
In contrast to the results presented here, other investiga-
tors (17, 21) have reported that TPCK does not inhibit the
DNA binding activity of NF-KB in vitro. This discrepancy
may be a result of the assay conditions in which the exper-
iments were performed. We have found that DTT suppresses
the in vitro inhibitory activity of TPCK toward NF-KB DNA
binding (Fig. 2D). It is possible that other investigators did
not detect the inhibitory effects of TPCK in vitro because
DTT was present. As our in vitro results are identical to those
observed in vivo, we believe that the in vitro conditions used
in this study more closely reflect protease inhibitor activity
within cells.
Protease Inhibitors Block Both Phosphorylation and Degra-
dation of IucBa in Vivo. Pretreatment of cells with TPCK
suppresses degradation of IKBa by inducers of NF-KB in-
cluding phorbol 12-myristate 13-acetate, interleukin 1p3, and
LPS (11, 15-17). We demonstrate here that the other tested
serine protease inhibitors, in addition to TPCK, also re-
pressed TNFa-induced degradation of IKBa in HeLa cells
(Fig. 3A). It is well established that TNFa-induced degrada-
tion of IKBa is preceded by its phosphorylation (8, 22).
Therefore, in the absence of degradation, phosphorylated
IKBa would be expected to accumulate in cells. However,
newly phosphorylated IKBa, as detected on a Western blot
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FIG. 2. In vitro effects of protease inhibitors on NF-KB DNA
binding. (A) Protease inhibitors prevent DNA binding of activated
nuclear NF-KB in vitro. Nuclear extracts from Jurkat cells stimulated
with TNFa for 15 min were incubated at 40C for 1 h alone or with
TPCK, TLCK, BTEE, or DCIC in the absence of DTT. DTT was
then added and samples were analyzed by EMSA. The final con-
centration of protease inhibitors is indicated. ns, Nonspecific band.
(B) Protease inhibitors prevent DOC-induced binding of cytoplasmic
NF-KB in vitro. Experiments using untreated Jurkat cytoplasmic
extracts were performed as described in A except for the in vitro
activation of NF-KB by DOC after the 1-h incubation at 40C with
protease inhibitors. The final concentration of protease inhibitor for
each sample is shown. (C) Protease inhibitors prevent DNA binding
of the bacterially expressed RelA subunit of NF-KB. Experiments
were performed as in A by using 1 A4 of RelA and the indicated
concentrations of protease inhibitors. (D) DTT suppresses the in-
hibitory effect of TPCK on NF-KB binding. As indicated, HeLa
nuclear extracts from cells treated with TNFa for 15 min were
incubated for 1 h at 40C alone, with 50 /AM TPCK, or with 50 pM
TPCK and the concentrations of DTT indicated. Afterwards, DTT
was added to 5 mM in all samples, which were then analyzed by
EMSA. NF-KB and the nonspecific (ns) band are labeled to the left;
free probe is not shown.
and based on its reduced mobility during SDS/PAGE (7, 8,
22), was not observed in samples stimulated with TNFa for
15 min in the presence of protease inhibitors (Fig. 3A). This
result indicates that protease inhibitors may prevent the
phosphorylation of IKBa in addition to its degradation. An-
other explanation is that IKBa is rapidly dephosphorylated by
a cytoplasmic phosphatase in the absence of degradation. To
distinguish between these possibilities, cytoplasmic extracts
from HeLa cells treated with TNFa for shorter periods of
time were examined. Stable phosphorylated IKBa can be
detected by Western blot analysis at these earlier time points
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FIG. 3. Protease inhibitors prevent TNFa-induced phosphoryla-
tion and degradation of IKBa. (A) Protease inhibitors block IKBa
degradation. HeLa cells, untreated or preincubated with the indi-
cated protease inhibitors, were induced with TNFa for 15 min.
Cytoplasmic extracts were then isolated and analyzed on a Western
blot by using a polyclonal IKBa antibody. Protease inhibitor con-
centrations and time of preincubation are as in Fig. 1. IKBa is
indicated at the left and the addition of TNFa (for 15 min) and
protease inhibitors is also indicated. No other bands were specifically
recognized by the antibody. (B) Protease inhibitors block IKBa
phosphorylation. Experiments were performed as inA except TNFa
induction was for 5 min. The phosphorylated form of IKBa induced
by TNFa, which has a reduced mobility on SDS/PAGE, is indicated
to the left. Samples were treated as indicated above the blot.
(8). Treatment of cells with TNFa alone for 5 min resulted in
the appearance ofphosphorylated IKBa. However, this form
of IKBa was not present when cells were first preincubated
with any of the protease inhibitors and then stimulated with
TNFa (Fig. 3B). Essentially identical results were obtained in
Jurkat cells (data not shown). Thus, these serine protease
inhibitors repress both the phosphorylation and degradation
of IcBa. Because the inhibitors block both phosphorylation
and degradation, it is difficult to assess from their use how
each event contributes to the activation of NF-KB.
Phosphorylated IncBaRens Associated with NF-#cB. To
better understand the mechanism(s) responsible for NF-KB
activation, we determined in vivo whether induced phosphor-
ylation of IKBa was sufficient for its dissociation from
NF-KB. Specifically, we ascertained whether the phosphor-
ylated form of IKBa observed after stimulation ofHeLa cells
with TNFa for 5 min could be coimmunoprecipitated with an
antibody to the RelA subunit of NF-cB. The results, shown
in Fig. 4A, indicate that phosphorylated IKBa remains asso-
ciated with NF-KB. Neither unphosphorylated nor phosphor-
ylated IicBa was detected when the RelA antibody used in the
immunoprecipitation or the IKBa antibody used in the West-
em blot was preincubated with its corresponding peptide,
demonstrating the specificity of the assay.
We also investigated whether similar results could be
observed for other inducers ofNF-KB. Studies have observed
that LPS activation of NF-KB in the monocytic cell line
THP-1 involves the phosphorylation and degradation ofIKBa
(ref. 7 and Fig. 4B). As shown in Fig. 4B, the phosphorylated
form of IKBa induced by LPS also retains association with
NF-KB. Okadaic acid, a specific inhibitor of the serine/
threonine phosphatases 1 and 2A, induces NF-KB DNA
binding activity in Jurkat T cells (23). This activation is
mediated primarily through the phosphorylation and degra-
dation of IKBa (T.S.F. and A.S.B., unpublished data). Con-
sistent with results obtained using TNFa and LPS, the
phosphorylated form of IxBa induced by okadaic acid also
remains complexed to NF-KB (Fig. 4B). It is evident from
these results that under a variety of conditions the inducible
phosphorylation ofIKBa does not cause its dissociation from
IKsB xf\._ -,
IKB~t I/
FIG. 4. Phosphorylation of IKBa is not sufficient for its disso-
ciation from NF-KB. (A) TNFa-induced phosphorylation of IKBa
does not cause its dissociation from NF-KB. NF-KB complexes from
cytoplasmic extracts of either untreated cells or cells treated with
TNFa for 5 min were immunoprecipitated with a ReIA polyclonal
antibody. Washed complexes, containing NF-KB and associated
proteins, were then treated with 0.8% DOC to release IKBa bound to
NF-KB. Liberated IKBa was subsequently analyzed on a Western
blot with an IKBa polyclonal antibody. Also shown is 50 ug of
cytoplasmic extract from untreated cells or cells stimulated with
TNFa for 5 min, neither of which underwent immunoprecipitation.
Sample treatment, including controls for specificity, was as indicated
above the blot. (B) Phosphorylated IKBa, induced by LPS orokadaic
acid, remains associated with NF-KB. Experiments were performed
as in A except cytoplasmic extracts from THP-1 cells treated 1 hr
with LPS or Jurkat T cells treated 1 h with okadaic acid were used.
As indicated, both cytoplasmic extracts and immunoprecipitations
using the RelA antibody were analyzed on a Western blot with the
IKBa antibody. The various forms of IKBa are indicated to the left
and the inducer is indicated to the right. CE, cytoplasmic extract; IP,
immunoprecipitation.
NF-KB. These data strongly suggest that other events signif-
icantly contribute to the activation of NF-KB.
DISCUSSION
In this report we demonstrate that protease inhibitors used
thus far in studies of NF-KB (11, 16-18) have previously
uncharacterized properties that may complicate conclusions
based on their use. For example, TPCK, TLCK, and DCIC
interfere with NF-KB DNA binding potential. It is known that
these inhibitors block protease activity by direct alkylation or
acylation of the protease active site (24-26). Moreover,
TPCK, TLCK, and DCIC alter the activity of proteins in
addition to proteases such as glycogen phosphorylase b,
TFIIIC, and Ets-1 through direct modifications (27-29).
Furthermore, NF-KB DNA binding activity is redox-
sensitive and can be inhibited by alkylation within its DNA
binding domain (30, 31). Based on these observations and the
data in this report, it is highly likely that the effects elicited
in vivo and in vitro by these agents on NF-KB DNA binding
occur through a direct modification of NF-KB and not by an
indirect effect. It is also apparent that NF-KB can be modified
when free or complexed to IKBa. An awareness of these
effects on NF-KB DNA binding will be beneficial during
relevant experiments and in the interpretation of results.
BTEE and AEBSF, protease inhibitors that do not appear to
interfere with NF-KB DNA binding activity, may be better
suited for studies of NF-KB.
We also show that all protease inhibitors that repress IKcBa
degradation also completely prevent its phosphorylation.
Therefore, it is difficult to conclude whether the suppressive
effects of these inhibitors on NF-KB activation are due to
Biochemistry: Finco et A
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their inhibition of IKBa phosphorylation or instead its deg-
radation. Several models exist to explain how these protease
inhibitors prevent IKBa phosphorylation. (i) The inhibitors
may target a protease that regulates a kinase responsible for
IKBa phosphorylation; inhibition of this putative upstream
protease would repress kinase activation and, therefore,
prevent IKBa phosphorylation. Thus, proteases potentially
exist at two steps in the NF-KB signal transduction pathway,
one upstream ofthe kinase and one that acts directly on IKBa.
(ii) It is conceivable that the protease inhibitors directly
interfere with a signal transduction component that is not a
protease but is essential for NF-KB activation. As described
in this report and others (27-29), TPCK, TLCK, and DCIC
can directly modify and inhibit the activity of nonproteolytic
proteins. Although BTEE and AEBSF do not effect NF-icB
DNA binding, they may alter the activity of proteins within
the cell besides proteases. This second model includes the
possibility that direct modification ofNF-KB and/or IKBa by
certain protease inhibitors may prevent their phosphoryla-
tion and/or activation. (iii) Phosphorylation and proteolysis
are coupled events. This model would be relevant in situa-
tions where the kinase and protease directly interact, for
example, as part ofa multiprotein complex. Interaction ofthe
protease inhibitors with the protease could cause a confor-
mational change in the complex that then alters kinase
activity. (iv) A combination of the above models may also
explain how all of these mechanistically distinct protease
inhibitors prevent IKBa phosphorylation; although the inhib-
itors are targeting different proteins in the signal transduction
pathway, the outcome is identical.
The identification ofinhibitors that block IKBa degradation
but allow phosphorylation may clarify the role of proteolysis
in NF-KB activation. Recently, an inhibitor of NF-KB acti-
vation that targets the proteasome has been shown to prevent
degradation ofIKBa without altering its phosphorylation (32).
Intriguingly, two ofthe protease inhibitors used in the present
study, DCIC and AEBSF, repress proteolytic activities
within the proteasome (33, 34). However, they must be
altering additional cellular processes due to their ability to
inhibit IKBa phosphorylation. DCIC and AEBSF may inter-
act with the proteasome in a manner that also inhibits IKBa
phosphorylation or an additional target ofDCIC and AEBSF
within the cell may be the proposed upstream protease.
Previous studies have suggested that the phosphorylation
of IKBa is responsible for its dissociation from NF-KB, after
which free IKBa is rapidly degraded (5, 6, 10, 15). However,
we show in this report that in vivo phosphorylation of IKBa
alone is not sufficient for its dissociation from NF-KB. This
important result indicates that additional cellular events are
required for NF-KB activation. Perhaps other phosphoryla-
tion events, either on IKBa or NF-KB, are necessary. Con-
sistent with this idea, we have observed that the ReLA subunit
ofNF-KB is also phosphorylated after treatment of cells with
inducers of NF-KB (unpublished observation). Thus, within
an NF-KB-IKBa complex, phosphorylation of NF-KB or
IKBa alone may have no consequence, but both phosphor-
ylation events together would cause the dissociation ofIKBa.
Another possible role for inducible phosphorylation of IKBa
is that it serves as a signal for a subsequent essential event.
For example, phosphorylated IKBa may be a better substrate
for a cytoplasmic protease. The proteolysis of phosphory-
lated IKBa complexed to NF-KB would then result in the
activation of NF-KB.
Elucidation of the signals required for NF-KB activation is
important in deciphering how this family of transcription
factors is regulated. An understanding of this complex pro-
cess may lead to the discovery of pharmacologic modulators
of NF-KB activity that are beneficial in the treatment of
immune and inflammation disorders, in the regulation of
tumorigenesis, and in the treatment of AIDS.
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